Miller W - Search Results

1

Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens.

Miskovsky E, Gershman K, Clements ML, Cupps T, Calandra G, Hesley T, Ioli V, Ellis R, Kniskern P, Miller W, et al. Miskovsky E, et al. Among authors: miller w. Vaccine. 1991 May;9(5):346-50. doi: 10.1016/0264-410x(91)90062-b. Vaccine. 1991. PMID: 1872019 Clinical Trial.

2

Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens.

Clements ML, Miskovsky E, Davidson M, Cupps T, Kumwenda N, Sandman LA, West D, Hesley T, Ioli V, Miller W, et al. Clements ML, et al. Among authors: miller w. J Infect Dis. 1994 Sep;170(3):510-6. doi: 10.1093/infdis/170.3.510. J Infect Dis. 1994. PMID: 8077707 Clinical Trial.

3

In vitro immune responses to hepatitis B surface antigens S and preS2 during acute infection by hepatitis B virus in humans.

Cupps TR, Hoofnagle JH, Ellis RW, Miller WJ, Gerin JL, Volkman DJ, Haas-Smith SA. Cupps TR, et al. Among authors: miller wj. J Infect Dis. 1990 Mar;161(3):412-9. doi: 10.1093/infdis/161.3.412. J Infect Dis. 1990. PMID: 2313122

4

Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A.

Ellerbeck EF, Lewis JA, Nalin D, Gershman K, Miller WJ, Armstrong ME, Davide JP, Rhoad AE, McGuire B, Calandra G, et al. Ellerbeck EF, et al. Among authors: miller wj. Vaccine. 1992;10(10):668-72. doi: 10.1016/0264-410x(92)90087-z. Vaccine. 1992. PMID: 1523877 Free article. Clinical Trial.

5

In vitro immune responses to hepatitis B surface antigen (Pre-S2 and S) following remote infection by hepatitis B virus in humans.

Cupps TR, Hoofnagle JH, Ellis RW, Miller WJ, Seeff L, Guerrera A, Gerin JL, Haas-Smith SA. Cupps TR, et al. Among authors: miller wj. J Clin Immunol. 1989 May;9(3):229-41. doi: 10.1007/BF00916819. J Clin Immunol. 1989. PMID: 2768432

6

In vitro T cell immune responses to the preS2 antigen of the hepatitis B virus envelope protein in preS2 + S vaccine recipients. Absence of cross-reactivity of subtypes at a major T cell recognition site.

Cupps TR, Tibbles J, Hurni WM, Miller WJ, Ellis RW, Milich D, Wetter N. Cupps TR, et al. Among authors: miller wj. J Immunol. 1993 Sep 15;151(6):3353-60. J Immunol. 1993. PMID: 7690803

7

Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations.

West DJ, Calandra GB, Hesley TM, Ioli V, Miller WJ. West DJ, et al. Among authors: miller wj. Vaccine. 1993;11 Suppl 1:S21-7. doi: 10.1016/0264-410x(93)90154-p. Vaccine. 1993. PMID: 8447168 Review.

8

Hepatitis B vaccines: blueprints for vaccines of the future.

Kniskern PJ, Miller WJ. Kniskern PJ, et al. Among authors: miller wj. Biotechnology. 1992;20:177-204. doi: 10.1016/b978-0-7506-9265-6.50014-2. Biotechnology. 1992. PMID: 1600381 Review. No abstract available.

9

A candidate vaccine for hepatitis B containing the complete viral surface protein.

Kniskern PJ, Hagopian A, Burke P, Dunn N, Emini EA, Miller WJ, Yamazaki S, Ellis RW. Kniskern PJ, et al. Among authors: miller wj. Hepatology. 1988 Jan-Feb;8(1):82-7. doi: 10.1002/hep.1840080117. Hepatology. 1988. PMID: 2448217

10

Antibody assays suitable for assessing immune responses to live varicella vaccine.

Provost PJ, Krah DL, Kuter BJ, Morton DH, Schofield TL, Wasmuth EH, White CJ, Miller WJ, Ellis RW. Provost PJ, et al. Among authors: miller wj. Vaccine. 1991 Feb;9(2):111-6. doi: 10.1016/0264-410x(91)90266-9. Vaccine. 1991. PMID: 1647574

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,158 results

Search Page

Filters